PMID- 10329919
OWN - NLM
STAT- MEDLINE
DCOM- 19990803
LR  - 20171116
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 84
IP  - 5
DP  - 1999 May
TI  - Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative
      disorders.
PG  - 413-8
AB  - BACKGROUND AND OBJECTIVE: Distinction between B-cell chronic leukemias can be
      difficult due to overlap in cell morphology and immunologic features. We
      investigated, by quantitative flow cytometry, the expression of CD79b, CD5 and
      CD19 in cells from a variety of B-cell disorders to see whether this analysis
      adds further information useful to the diagnosis and characterization of these
      diseases. DESIGN AND METHODS: Peripheral blood cells from 6 normal individuals
      were used as reference controls. The diseases of the 63 patients investigated
      comprised: 29 chronic lymphocytic leukemia (CLL), six of them with atypical
      morphology, 6 B-cell prolymphocytic leukemia (PLL), 12 splenic lymphoma with
      villous lymphocytes (SLVL) and 16 mantle-cell (Mc) lymphoma in leukemic phase.
      The study was carried out by triple immunostaining with directly conjugated
      monoclonal antibodies (MoAb) against CD79b, CD5 and CD19 and quantitative
      estimation of the antigens per cell assessed with standard microbeads (Quantum
      Simply Cellular). RESULTS: Compared to normal B-cells, the number of CD19
      molecules was significantly lower in cells from all of the B-cell disorders
      except PLL. The intensity of CD5 in leukemic B-cells was significantly higher in 
      CLL cells, including atypical cases, and Mc lymphoma than in normal B-cells,
      whilst PLL and SLVL had values similar to those of normal B-lymphocytes. CD79b
      was expressed at lower levels in all types of leukemic cells compared to normal
      B-lymphocytes but differences were statistically significant in CLL, Mc lymphoma 
      and SLVL. The number of CD79b molecules per cell was significantly lower in
      typical CLL than in the remaining B-cell diseases whilst the comparison of CD5
      and CD19 intensity between CLL and non-CLL samples failed to show any
      statistically significant difference. INTERPRETATION AND CONCLUSIONS: Distinct
      antigen density patterns for the various conditions emerged from this analysis:
      Typical CLL was characterized by moderate CD5 and weak or negative CD79b
      expression. Mc lymphoma showed an homogeneous pattern, characterized by similar
      expression of CD5 than CLL but significantly stronger expression of CD79b whilst 
      PLL and SLVL had weak CD5 and moderate CD79b expression. Atypical CLL had an
      intermediate pattern of CD79b antigen expression ranging from weak to moderate
      with bright CD5. Unlike CD5 and CD79b, CD19 did not discriminate the various
      B-cell disorders but only between normal and leukemic cells.
FAU - Cabezudo, E
AU  - Cabezudo E
AD  - Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital
      and Institute of Cancer Research, London, UK.
FAU - Carrara, P
AU  - Carrara P
FAU - Morilla, R
AU  - Morilla R
FAU - Matutes, E
AU  - Matutes E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD19)
RN  - 0 (CD5 Antigens)
RN  - 0 (CD79 Antigens)
RN  - 0 (CD79B protein, human)
SB  - IM
MH  - Antigens, CD/*blood
MH  - Antigens, CD19/*blood
MH  - CD5 Antigens/*blood
MH  - CD79 Antigens
MH  - Case-Control Studies
MH  - Humans
MH  - Leukemia, B-Cell/*immunology
MH  - Lymphoma, B-Cell/*immunology
EDAT- 1999/05/18 00:00
MHDA- 1999/05/18 00:01
CRDT- 1999/05/18 00:00
PHST- 1999/05/18 00:00 [pubmed]
PHST- 1999/05/18 00:01 [medline]
PHST- 1999/05/18 00:00 [entrez]
PST - ppublish
SO  - Haematologica. 1999 May;84(5):413-8.